Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

CEPI funds Bundibugyo Ebola vaccine candidate into clinicHealth — 5dCEPI announced up to $16.5 million to Minapharm/ProBioGen to advance Bundibugyo ebolavirus vaccine into early-stage human trials in Africa, marking the fifth Bundibugyo-specific candidate it backs and aiming to have at least two vaccines reach Emergency Use Authorization and WHO prequalification amid the DRC outbreak. The UN warns the outbreak is the largest and fastest-growing in DRC and seeks about $1.1 billion, while CEPI grapples with a substantial funding shortfall despite borrowing $100 million from existing programs and additional pledges to push vaccine development forward.

DRC receives 70,000 Ervebo vaccines to bolster frontline Ebola response — Aug 20, 2026The WHO and partners have allocated 70,000 Ervebo Ebola vaccine doses to the Democratic Republic of Congo to bolster the response to the Bundibugyo-driven outbreak, with 50,000 earmarked for frontline health workers and 20,000 for a late-stage trial to determine cross-protection against Bundibugyo. The deployment occurs amid the fastest, deadliest Ebola surge in the country’s history, and while Ervebo is approved for Zaire ebolavirus, its effectiveness against Bundibugyo remains under study.